The demonstrated activity of orally administered BPC-157 in gastrointestinal models confirms sufficient stability in gastric juice and resistance to complete enzymatic degradation during intestinal transit, at least for local mucosal effects if not systemic absorption
DAgostino, I., Tacconelli, S., Bruno, A., Contursi, A., Mucci, L., Hu, X., Xie, Y., Chakraborty, R., Jain, K., Sacco, A., Zucchelli, M., Landolfi, R., Dovizio, M., Falcone, L., Ballerini, P., Hwa, J., & Patrignani, P
Deterioration of sleep quality according to glycemic status
5-amino-1MQ 30 , 5-amino-1MQ 30 Special Force Pharm